Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04375527 | Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma | terminated | Phase 2 | 3 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT05744128 | CD8 Minibody Repeatability Study(PRETZCEL) | terminated | Phase 2 | 3 | ImaginAb, Inc.INDUSTRY | 1 | Dec 3, 2024 | clinicaltrials |
| NCT05457842 | A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery | terminated | Phase 2 | 1 | Astellas Pharma IncINDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT01217411 | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | terminated | Phase 2 | 315 | Novartis PharmaceuticalsINDUSTRY | 15 | Oct 9, 2024 | clinicaltrials |
| NCT00863330 | Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma | terminated | Phase 2 | 14 | Wake Forest University Health SciencesOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT03476174 | Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma | terminated | Phase 2 | 1 | Ralph HaukeOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT05200143 | Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma | terminated | Phase 2 | 4 | Providence Health & ServicesOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04768881 | Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma | terminated | Phase 2 | 15 | Karyopharm Therapeutics IncINDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT04198818 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors | terminated | Phase 1 / Phase 2 | 37 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jul 19, 2024 | clinicaltrials |
| NCT04924413 | L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma | terminated | Phase 2 | 9 | Quanli GaoOTHER_GOV | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04655157 | Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma(QUAD01) | terminated | Phase 1 / Phase 2 | 2 | Jason J. Luke, MDOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT02621515 | Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases(CA209-322) | terminated | Phase 2 | 7 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT00199342 | A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma | terminated | Phase 1 / Phase 2 | 5 | Kyowa Kirin, Inc.INDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT05709821 | IMM60 and Pembrolizumab in Melanoma and NSCLC | terminated | Phase 1 / Phase 2 | 1 | iOx TherapeuticsINDUSTRY | 3 | Apr 24, 2024 | clinicaltrials |
| NCT05050006 | ITIL-168 in Advanced Melanoma(DELTA-1) | terminated | Phase 2 | 29 | Instil BioINDUSTRY | 3 | Apr 16, 2024 | clinicaltrials |
| NCT02978443 | A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | terminated | Phase 2 | 14 | Georgetown UniversityOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT04899921 | Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets | terminated | Phase 2 | 1 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT00003552 | Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma | terminated | Phase 1 / Phase 2 | — | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT04455503 | Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 | terminated | Phase 1 / Phase 2 | 15 | Evaxion Biotech A/SINDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05060003 | Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection | terminated | Phase 2 | 7 | Washington University School of MedicineOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04337931 | A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma | terminated | Phase 2 | 45 | Apexigen America, Inc.INDUSTRY | 2 | Feb 13, 2024 | clinicaltrials |
| NCT04894994 | FLX475 in Combination With Ipilimumab in Advanced Melanoma | terminated | Phase 2 | 6 | RAPT Therapeutics, Inc.INDUSTRY | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04589832 | Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 6 | Arkadiusz Z. Dudek, MDOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT04785365 | Long-Term Follow-Up Study of Patients Receiving ATL001 | terminated | Phase 2 | 1 | Achilles Therapeutics UK LimitedINDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT02425306 | Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma(Mel63; CHAMP) | terminated | Phase 1 / Phase 2 | 48 | Craig L Slingluff, JrOTHER | 1 | Oct 30, 2023 | clinicaltrials |
| NCT02743611 | Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 4 | Bellicum PharmaceuticalsINDUSTRY | 1 | Oct 5, 2023 | clinicaltrials |
| NCT02831933 | Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma(ENSIGN) | terminated | Phase 2 | 11 | Eric Bernicker, MDOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03430947 | Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases(RadioCoBRIM) | terminated | Phase 2 | 20 | Technische Universität DresdenOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT02740920 | Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker | terminated | Phase 2 | 9 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 25, 2023 | clinicaltrials |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors(ALpha-T) | terminated | Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT02748564 | Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | terminated | Phase 2 | 10 | Rutgers, The State University of New JerseyOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT02203604 | High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery | terminated | Phase 2 | 9 | CINJRegulatoryOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT00104884 | FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma | terminated | Phase 2 | 4 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Jun 28, 2023 | clinicaltrials |
| NCT01559818 | A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001 | terminated | Phase 1 / Phase 2 | 10 | Immodulon Therapeutics LtdINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03637803 | Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors | terminated | Phase 1 / Phase 2 | 63 | 4D pharma plcINDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT01995344 | TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment(METILDA) | terminated | Phase 2 | 2 | The Christie NHS Foundation TrustOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05234437 | A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma | terminated | Phase 2 | 1 | QBiotics Group LimitedINDUSTRY | 1 | Apr 19, 2023 | clinicaltrials |
| NCT02054520 | Immunotherapy Study for Patients With Stage IV Melanoma | terminated | Phase 2 | 47 | NewLink Genetics CorporationINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04834973 | A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma | terminated | Phase 1 / Phase 2 | 3 | QBiotics Group LimitedINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT00667953 | Study of Temzolomide and Gleevec in Advanced Melanoma | terminated | Phase 1 / Phase 2 | 32 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT02771626 | Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 / Phase 2 | 118 | Calithera Biosciences, IncINDUSTRY | 1 | Mar 17, 2023 | clinicaltrials |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies(REVEAL) | terminated | Phase 1 / Phase 2 | 64 | Nektar TherapeuticsINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT02052193 | Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study | terminated | Phase 2 | 8 | University Hospital TuebingenOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Rubius TherapeuticsINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT02414750 | Vemurafenib Plus Cobimetinib in Metastatic Melanoma(REPOSIT) | terminated | Phase 2 | 78 | Netherlands Working Group on Immunotherapy of OncologyOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT00945269 | Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma | terminated | Phase 1 / Phase 2 | 3 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT00145158 | Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma | terminated | Phase 1 / Phase 2 | 23 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT00145145 | Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 1 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 7, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Dec 4, 2024source: clinicaltrials